New pill aims to curb alcohol cravings in early trial

NCT ID NCT07520292

Recruiting now Disease control Sponsor: Newleos Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called NTX-2001 in 50 adults with alcohol use disorder. Participants take the drug or a placebo daily for two weeks. Researchers will measure how much alcohol they drink and check for side effects. The goal is to see if this drug can safely reduce drinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NTX-2001 (a drug that targets a brain receptor to reduce alcohol cravings)
What this could lead to: If successful, this could point toward a new medication to help people with alcohol use disorder drink less.
What could go wrong: This is a very early (Phase 1b) proof-of-concept study with only 50 people. It may not show a clear benefit, and the drug could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Show contact details

Locations

Yale University School of Medicine, Connecticut Mental Health Center
RECRUITING

New Haven, Connecticut, 06519, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.